Wird geladen...
Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data
BACKGROUND: No studies have directly compared the effectiveness and safety of dabigatran and rivaroxaban using US Medicare data. The objective of the study was to compare the effectiveness and safety between rivaroxaban 20mg/dabigatran 150mg, or rivaroxaban 15mg/dabigatran 75mg among atrial fibrilla...
Gespeichert in:
| Veröffentlicht in: | Am J Cardiovasc Drugs |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6572759/ https://ncbi.nlm.nih.gov/pubmed/27637493 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40256-016-0189-9 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|